Drug Interaction Report

ADJUST DOSING INTERVAL: Coadministration with bile acid sequestrants may reduce the absorption and systemic exposure of the peroxisome proliferator-activated receptor (PPAR) agonists, elafibranor and seladelpar, potentially reducing their efficacy. In general, bile acid sequestrants are anion exchange resins which bind bile acids in the intestine. Therefore, it is possible for the bile acid sequestrant to bind to an anionic drug like elafibranor or seladelpar, forming an insoluble complex that is excreted in the feces without being absorbed systemically.

MANAGEMENT: If concomitant use is required, the PPAR agonist (elafibranor or seladelpar) should be administered at least 4 hours before or 4 hours after administration of the bile acid sequestrant, or at as great an interval as possible.